G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/05/2791050/0/en/G1-Therapeutics-Presents-New-Post-Hoc-Analyses-Indicating-That-Patients-Who-Previously-Received-Trilaciclib-Have-Improved-Overall-Survival-with-Subsequent-Anticancer-Therapy.html

– Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved Long-Term Survival with Subsequent Anticancer Therapies –

Read more at globenewswire.com

Related news for (GTHX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.